Keloids represent a persistent clinical challenge, with recurrence rates approaching 100% after conventional surgical excision. Historically viewed as fibroblast-driven scars, emerging evidence positions immune dysregulation as a central driver of keloid pathogenesis, reshaping diagnostic and therapeutic paradigms.
Recent Advances:
Multi-omics and single-cell analyses reveal profound alterations in immune cell populations and cytokine networks within keloid tissue. M2 macrophages, mast cells, Th2 and Th17 subsets, and dendritic cells dominate the inflammatory microenvironment, sustaining fibroblast activation and excessive extracellular matrix deposition. Key signaling axes—including transforming growth factor-β (TGF-β)/Smad, IL-4/IL-13, IL-6/JAK-STAT-3, and PI3K/AKT/mTOR—intersect with mechanical stress pathways, creating a self-perpetuating fibrotic loop. Notably, soluble human leukocyte antigen-E emerges as a predictive biomarker for disease progression and recurrence, while tissue-resident memory T cells may underlie postoperative relapse.
Therapeutic Implications:
Beyond corticosteroids and silicone gel, immune-targeted strategies are gaining traction. Dupilumab (IL-4/IL-13 blockade) demonstrates clinical efficacy in reducing keloid burden and pruritus. Experimental approaches targeting TGF-β signaling (Fresolizumab, AVID200), NKG2A/CD94 checkpoints (Monalizumab), IL-6 (Tocilizumab), and TSLP (Tezepelumab) hold promise for precision immunotherapy. Localized delivery and combination regimens may optimize outcomes while minimizing systemic toxicity.
Critical Issues and Future Directions:
The absence of validated keloid models and large-scale trials limits translation. Future research must integrate immune profiling, biomarker validation, and mechanistic modeling to enable personalized interventions. Immune dysregulation is not merely an epiphenomenon—it is the Achilles’ heel of keloids, offering unprecedented opportunities for targeted therapy and recurrence prevention.
WangY, WangX, YuanZ, et al.Identifying potential drug targets for keloid: A mendelian randomization study. J Invest Dermatol, 2025; 145(1):77–84.e6.
2.
EksteinSF, WylesSP, MoranSL, et al.Keloids: A review of therapeutic management. Int J Dermatol, 2021; 60(6):661–671.
3.
XuH, ZhuZ, HuJ, et al.Downregulated cytotoxic CD8+ T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids. Cell Mol Immunol, 2022; 19(4):527–539.
4.
DauradeM, BretonP, RouardN, et al.Efficacy of surgical excision and brachytherapy in the treatment of keloids: A retrospective cohort study. Adv Skin Wound Care, 2020; 33(11):1–6.
5.
CheK, LyuQ, MaG. Comparative efficacy and safety of common therapies in keloids and hypertrophic scars: A systematic review and meta-analysis. Aesthetic Plast Surg, 2021; 45(1):372–373.
6.
FuS, DuanL, ZhongY, et al.Comparison of surgical excision followed by adjuvant radiotherapy and laser combined with steroids for the treatment of keloids: A systematic review and meta-analysis. Int Wound J, 2024; 21(3):e14449.
7.
AndrewsJP, MarttalaJ, MacarakE, et al.Keloids: The paradigm of skin fibrosis - Pathomechanisms and treatment. Matrix Biol, 2016; 51:37–46.
8.
QiW, XiaoX, TongJ, et al.Progress in the clinical treatment of keloids. Front Med (Lausanne), 2023; 10:1284109.
9.
LiuY, XiongX, CaoN, et al.Diagnosis and treatment of keloid: Method summary and effect evaluation. Clin Cosmet Investig Dermatol, 2023; 16:3775–3783.
10.
YagiKI, DafallaAA, OsmanAA. Does an immune reaction to sebum in wounds cause keloid scars? Beneficial effect of desensitisation. Br J Plast Surg, 1979; 32(3):223–225.
11.
BlochEF, HallMGJr, DensonMJ, et al.General immune reactivity in keloid patients. Plast Reconstr Surg, 1984; 73(3):448–451.
12.
DirandZ, MarauxM, TissotM, et al.Macrophage phenotype is determinant for fibrosis development in keloid disease. Matrix Biol, 2024; 128:79–92.
13.
LiL, CaoJ, LiS, et al.M2 macrophage-derived sEV regulate pro-inflammatory ccr2+macrophage subpopulations to favor post-AMI cardiac repair. Adv Sci (Weinh), 2023; 10(14):e2202964.
14.
HeskethM, SahinKB, WestZE, et al.Macrophage phenotypes regulate scar formation and chronic wound healing. Int J Mol Sci, 2017; 18(7):1545.
15.
DengT, XuJ, WangQ, et al.Immunomodulatory effects of curcumin on macrophage polarization in rheumatoid arthritis. Front Pharmacol, 2024; 15:1369337.
16.
XuX, GuS, HuangX, et al.The role of macrophages in the formation of hypertrophic scars and keloids. Burns Trauma, 2020; 8:tkaa006.
17.
ZhaoT, ChuZ, ChuCH, et al.Macrophages induce gingival destruction via Piezo1-mediated MMPs-degrading collagens in periodontitis. Front Immunol, 2023; 14:1194662.
18.
ZhouB, GaoZ, LiuW, et al.Important role of mechanical microenvironment on macrophage dysfunction during keloid pathogenesis. Exp Dermatol, 2022; 31(3):375–380.
19.
ZhouX, FranklinRA, AdlerM, et al.Circuit design features of a stable two-cell system. Cell, 2018; 172(4):744–757.e17.
20.
DufourAM, AlvarezM, RussoB, et al.Interleukin-6 and type-I collagen production by systemic sclerosis fibroblasts are differentially regulated by interleukin-17A in the presence of transforming growth factor-beta 1. Front Immunol, 2018; 9:1865.
21.
ZhangQ, KellyAP, WangL, et al.Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways. J Invest Dermatol, 2006; 126(12):2607–2613.
22.
KidzeruEB, LebekoM, SharmaJR, et al.Immune cells and associated molecular markers in dermal fibrosis with focus on raised cutaneous scars. Exp Dermatol, 2023; 32(5):570–587.
23.
YeoE, ShimJ, OhSJ, et al.Revisiting roles of mast cells and neural cells in keloid: Exploring their connection to disease activity. Front Immunol, 2024; 15:1339336.
24.
WangR, ChenJ, ZhangZ, et al.Role of chymase in the local renin-angiotensin system in keloids: Inhibition of chymase may be an effective therapeutic approach to treat keloids. Drug Des Devel Ther, 2015; 9:4979–4988.
25.
KawajiriA, LiJ, KoinumaK, et al.Naturally arising memory-phenotype CD4+ T lymphocytes contain an undifferentiated population that can generate TH1, TH17, and Treg cells. Sci Adv, 2024; 10(49):eadq6618.
26.
AghaeeF, AbedinpourM, AnvariS, et al.Natural killer cells in multiple sclerosis: Foe or friends? Front Cell Neurosci, 2025; 19:1500770.
27.
WynnTA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol, 2004; 4(8):583–594.
28.
HawashAA, IngrasciG, NouriK, et al.Pruritus in keloid scars: Mechanisms and treatments. Acta Derm Venereol, 2021; 101(10):adv00582.
29.
ZhouB, ZhouN, LiuY, et al.Identification and validation of CCR5 linking keloid with atopic dermatitis through comprehensive bioinformatics analysis and machine learning. Front Immunol, 2024; 15:1309992.
30.
BittermanD, WangJY, CollinsA, et al.The role of IL-17 and Th17 cells in keloid pathogenesis. Arch Dermatol Res, 2024; 316(9):626.
31.
QiY, MaG. Comprehensive bioinformatic analysis reveals a fibroblast-related gene signature for the diagnosis of keloids. Heliyon, 2024; 10(15):e35011.
32.
WulffBC, ParentAE, MeleskiMA, et al.Mast cells contribute to scar formation during fetal wound healing. J Invest Dermatol, 2012; 132(2):458–465.
33.
WuJ, Del DucaE, EspinoM, et al.RNA sequencing keloid transcriptome associates keloids with Th2, Th1, Th17/Th22, and JAK3-Skewing. Front Immunol, 2020; 11:597741.
34.
ArbiS, EksteenEC, OberholzerHM, et al.Premature collagen fibril formation, fibroblast-mast cell interactions and mast cell-mediated phagocytosis of collagen in keloids. Ultrastruct Pathol, 2015; 39(2):95–103.
35.
AmmendolaM, ZuccalàV, PatrunoR, et al.Tryptase-positive mast cells and angiogenesis in keloids: A new possible post-surgical target for prevention. Updates Surg, 2013; 65(1):53–57.
36.
DongX, ZhangC, MaS, et al.Mast cell chymase in keloid induces profibrotic response via transforming growth factor-β1/Smad activation in keloid fibroblasts. Int J Clin Exp Pathol, 2014; 7(7):3596–3607.
37.
YuY, WuH, ZhangQ, et al.Emerging insights into the immunological aspects of keloids. J Dermatol, 2021; 48(12):1817–1826.
38.
ShanM, LiuH, HaoY, et al.The role of CD28 and CD8+ T cells in keloid development. Int J Mol Sci, 2022; 23(16):8862.
39.
ShimbaA, IkutaK. Control of immunity by glucocorticoids in health and disease. Semin Immunopathol, 2020; 42(6):669–680.
40.
ChenZ, ZhouL, WonT, et al.Characterization of CD45RO+ memory T lymphocytes in keloid disease. Br J Dermatol, 2018; 178(4):940–950.
41.
AriottiS, HogenbirkMA, DijkgraafFE, et al.T cell memory. Skin-resident memory CD8+ T cells trigger a state of tissue-wide pathogen alert. Science, 2014; 346(6205):101–105.
42.
ChenL, ShenZ. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders. Cell Mol Immunol, 2020; 17(1):64–75.
43.
DiazA, TanK, HeH, et al.Keloid lesions show increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy. J Eur Acad Dermatol Venereol, 2020; 34(4):e161–e164.
44.
MuraoN, SeinoK, HayashiT, et al.Treg-enriched CD4+ T cells attenuate collagen synthesis in keloid fibroblasts. Exp Dermatol, 2014; 23(4):266–271.
45.
ChenY, JinQ, FuX, et al.Connection between T regulatory cell enrichment and collagen deposition in keloid. Exp Cell Res, 2019; 383(2):111549.
46.
XuW, SinakiDG, TangY, et al.Acne-induced pathological scars: Pathophysiology and current treatments. Burns Trauma, 2024; 12:tkad060.
47.
VillaltaSA, RosenthalW, MartinezL, et al.Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med, 2014; 6(258):258ra142.
48.
BoyceDE, CiampoliniJ, RugeF, et al.Inflammatory-cell subpopulations in keloid scars. Br J Plast Surg, 2001; 54(6):511–516.
49.
RathM, PitiotA, KirrM, et al.Multi-antigen imaging reveals inflammatory DC, ADAM17 and neprilysin as effectors in keloid formation. Int J Mol Sci, 2021; 22(17):9417.
LagaresD, Ghassemi-KakroodiP, TremblayC, et al.ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis. Nat Med, 2017; 23(12):1405–1415.
52.
XiaoK, WangS, ChenW, et al.Identification of novel immune-related signatures for keloid diagnosis and treatment: Insights from integrated bulk RNA-seq and scRNA-seq analysis. Hum Genomics, 2024; 18(1):80.
53.
DengCC, XuXY, ZhangY, et al.Single-cell RNA-seq reveals immune cell heterogeneity and increased Th17 cells in human fibrotic skin diseases. Front Immunol, 2025; 15:1522076.
54.
XiaY, WangY, HaoY, et al.Multi-omics integrative analysis reveals the role of tumor necrosis factor superfamily member 4 in keloidal scarring. Am J Transl Res, 2023; 15(3):1607–1625.
55.
YangH, LvD, LiX, et al.Comprehensive analysis of keloid super-enhancer networks reveals FOXP1-mediated anti-senescence mechanisms in fibrosis. Cell Mol Biol Lett, 2025; 30(1):88.
56.
JinQ, GuiL, NiuF, et al.Macrophages in keloid are potent at promoting the differentiation and function of regulatory T cells. Exp Cell Res, 2018; 362(2):472–476.
57.
SchmidtA, OberleN, KrammerPH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol, 2012; 3:51.
58.
LiuS, YangH, SongJ, et al.Keloid: Genetic susceptibility and contributions of genetics and epigenetics to its pathogenesis. Exp Dermatol, 2022; 31(11):1665–1675.
59.
LiY, LiM, QuC, et al.The polygenic map of keloid fibroblasts reveals fibrosis-associated gene alterations in inflammation and immune responses. Front Immunol, 2021; 12:810290.
60.
HarnHI, OgawaR, HsuCK, et al.The tension biology of wound healing. Exp Dermatol, 2019; 28(4):464–471.
ČomaM, FröhlichováL, UrbanL, et al.Molecular changes underlying hypertrophic scarring following burns involve specific deregulations at all wound healing stages (inflammation, proliferation and maturation). Int J Mol Sci, 2021; 22(2):897.
63.
WilgusTA, WulffBC. The importance of mast cells in dermal scarring. Adv Wound Care (New Rochelle), 2014; 3(4):356–365.
64.
YounanGJ, HeitYI, DastouriP, et al.Mast cells are required in the proliferation and remodeling phases of microdeformational wound therapy. Plast Reconstr Surg, 2011; 128(6):649e–658e.
65.
WokalekH, RuhH. Time course of wound healing. J Biomater Appl, 1991; 5(4):337–362.
66.
EvansRA, TianYC, SteadmanR, et al.TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp Cell Res, 2003; 282(2):90–100.
67.
ShiZ, YaoC, ShuiY, et al.Research progress on the mechanism of angiogenesis in wound repair and regeneration. Front Physiol, 2023; 14:1284981.
68.
PakyariM, FarrokhiA, MaharlooeiMK, et al.Critical role of transforming growth factor beta in different phases of wound healing. Adv Wound Care (New Rochelle), 2013; 2(5):215–224.
69.
ŽivicováV, LacinaL, MateuR, et al.Analysis of dermal fibroblasts isolated from neonatal and child cleft lip and adult skin: Developmental implications on reconstructive surgery. Int J Mol Med, 2017; 40(5):1323–1334.
70.
LandénNX, LiD, StåhleM. Transition from inflammation to proliferation: A critical step during wound healing. Cell Mol Life Sci, 2016; 73(20):3861–3885.
71.
PoolJG. Normal hemostatic mechanisms: A review. Am J Med Technol, 1977; 43(8):776–780.
72.
RodriguesM, KosaricN, BonhamCA, et al.Wound healing: A cellular perspective. Physiol Rev, 2019; 99(1):665–706.
73.
MenterDG, KopetzS, HawkE, et al.Platelet “first responders” in wound response, cancer, and metastasis. Cancer Metastasis Rev, 2017; 36(2):199–213.
74.
BarleonB, SozzaniS, ZhouD, et al.Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood, 1996; 87(8):3336–3343.
75.
GamilHD, KhattabFM, El FawalMM, et al.Comparison of intralesional triamcinolone acetonide, botulinum toxin type A, and their combination for the treatment of keloid lesions. J Dermatolog Treat, 2020; 31(5):535–544.
76.
GoldMH, McGuireM, MustoeTA, et al.; International Advisory Panel on Scar Management. Updated international clinical recommendations on scar management: Part 2–algorithms for scar prevention and treatment. Dermatol Surg, 2014; 40(8):825–831.
77.
RanaK, PaniT, JhaSK, et al.Hydrogel-mediated topical delivery of steroids can effectively alleviate psoriasis via attenuating the autoimmune responses. Nanoscale, 2022; 14(10):3834–3848.
78.
MustoeTA, CooterRD, GoldMH, et al.; International Advisory Panel on Scar Management. International clinical recommendations on scar management. Plast Reconstr Surg, 2002; 110(2):560–571.
79.
HuangJ, YuS, LuoJ, et al.IFN-γ could induce ferroptosis in keloid fibroblasts by inhibiting the expression of serpine2. Cell Death Discov, 2025; 11(1):217.
80.
BermanB, FloresF. The treatment of hypertrophic scars and keloids. Eur J Dermatol, 1998; 8(8):591–595.
81.
MonstreyS, MiddelkoopE, VranckxJJ, et al.Updated scar management practical guidelines: Non-invasive and invasive measures. J Plast Reconstr Aesthet Surg, 2014; 67(8):1017–1025.
82.
FultonJE.Jr., Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloid scars. Dermatol Surg, 1995; 21(11):947–951.
83.
MiwaS, YokotaM, UeyamaY, et al.Discovery of selective transforming growth factor β type II receptor inhibitors as antifibrosis agents. ACS Med Chem Lett, 2021; 12(5):745–751.
84.
RiceLM, PadillaCM, McLaughlinSR, et al.Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest, 2015; 125(7):2795–2807.
85.
TremblayD, MascarenhasJ. Next generation therapeutics for the treatment of myelofibrosis. Cells, 2021; 10(5):1034.
86.
VarricchioL, Iancu-RubinC, UpadhyayaB, et al.TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight, 2021; 6(18):e145651.
87.
LiJ, LiZ, WangS, et al.Exosomes from human adipose-derived mesenchymal stem cells inhibit production of extracellular matrix in keloid fibroblasts via downregulating transforming growth factor-β2 and Notch-1 expression. Bioengineered, 2022; 13(4):8515–8525.
88.
LuoL, LiJ, WuY, et al.Adiponectin, but not TGF-β1, CTGF, IL-6 or TNF-α, may be a potential anti-inflammation and anti-fibrosis factor in keloid. J Inflamm Res, 2021; 14:907–916.
89.
KimBG, MalekE, ChoiSH, et al.Novel therapies emerging in oncology to target the TGF-β pathway. J Hematol Oncol, 2021; 14(1):55.
AndréP, DenisC, SoulasC, et al.Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell, 2018; 175(7):1731–1743.e13.
92.
Guttman-YasskyE, BissonnetteR, UngarB, et al.Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol, 2019; 143(1):155–172.
93.
SimpsonEL, BieberT, Guttman-YasskyE, et al.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med, 2016; 375(24):2335–2348.
94.
KangS, TanakaT, NarazakiM, et al.Targeting interleukin-6 signaling in clinic. Immunity, 2019; 50(4):1007–1023.
95.
KhannaD, LinCJF, FurstDE, et al.Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: Open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med, 2022; 205(6):674–684.
96.
FujitaM, YamamotoY, JiangJJ, et al.NEDD4 Is Involved in Inflammation Development during Keloid Formation. J Invest Dermatol, 2019; 139(2):333–341.
97.
MorianaC, MoulinetT, JaussaudR, et al.JAK inhibitors and systemic sclerosis: A systematic review of the literature. Autoimmun Rev, 2022; 21(10):103168.
98.
LimIJ, PhanTT, TanEK, et al.Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloids. J Biol Chem, 2003; 278(42):40851–40858.
99.
QianL, WangQ, WeiC, et al.Protein tyrosine phosphatase 1B regulates fibroblasts proliferation, motility and extracellular matrix synthesis via the MAPK/ERK signalling pathway in keloid. Exp Dermatol, 2022; 31(2):202–213.
100.
LiQ, ChenH, LiuY, et al.Osteomodulin contributes to keloid development by regulating p38 MAPK signaling. J Dermatol, 2023; 50(7):895–905.
101.
LvW, WuM, RenY, et al.Treatment of keloids through Runx2 siRNA-induced inhibition of the PI3K/AKT signaling pathway. Mol Med Rep, 2021; 23(1):55.
102.
TangZ, CaoY, DingJ, et al.Wubeizi ointment suppresses keloid formation through modulation of the mTOR pathway. Biomed Res Int, 2020; 2020:3608372.
103.
TuT, HuangJ, LinM, et al.CUDC-907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2. Int J Mol Med, 2019; 44(5):1789–1800.
104.
GauthierNC, Roca-CusachsP. Mechanosensing at integrin-mediated cell-matrix adhesions: From molecular to integrated mechanisms. Curr Opin Cell Biol, 2018; 50:20–26.
105.
LeaskA. Integrin β1: A mechanosignaling sensor essential for connective tissue deposition by fibroblasts. Adv Wound Care (New Rochelle), 2013; 2(4):160–166.
106.
ZanconatoF, CordenonsiM, PiccoloS. YAP and TAZ: A signalling hub of the tumour microenvironment. Nat Rev Cancer, 2019; 19(8):454–464.
107.
JainR, WatsonU, VasudevanL, et al.ERK activation pathways downstream of GPCRs. Int Rev Cell Mol Biol, 2018; 338:79–109.
108.
KhorshidFA. Comparative study of keloid formation in humans and laboratory animals. Med Sci Monit, 2005; 11(7):BR212–BR219.
109.
ZhangQ, YamazaT, KellyAP, et al.Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis. PLoS One, 2009; 4(11):e7798.
110.
ZhangT, WangXF, WangZC, et al.Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation. Biomed Pharmacother, 2020; 129:110287.
111.
SuppDM. Animal models for studies of keloid scarring. Adv Wound Care (New Rochelle), 2019; 8(2):77–89.
112.
NathansJF, AyersJL, ShendureJ, et al.Genetic tools for cell lineage tracing and profiling developmental trajectories in the skin. J Invest Dermatol, 2024; 144(5):936–949.
113.
ShafferJJ, TaylorSC, Cook-BoldenF. Keloidal scars: A review with a critical look at therapeutic options. J Am Acad Dermatol, 2002; 46(2 Suppl Understanding):S63–S97.
114.
Amini-NikS, YousufY, JeschkeMG. Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions. Adv Drug Deliv Rev, 2018; 123:135–154.
115.
TraceAP, EnosCW, MantelA, et al.Keloids and hypertrophic scars: A spectrum of clinical challenges. Am J Clin Dermatol, 2016; 17(3):201–223.
116.
EulerT, ValeskyEM, MeissnerM, et al.Normal and keloid fibroblasts are differentially influenced by IFN-γ and triamcinolone as well as by their combination. Wound Repair Regen, 2019; 27(5):450–461.
117.
ZhouH, YangP, ZhangT, et al.The role of apoptosis, immunogenic cell death, and macrophage polarization in carbon ion radiotherapy for keloids: Targeting the TGF-β1/SMADs signaling pathway. Biochim Biophys Acta Mol Basis Dis, 2025; 1871(1):167499.
118.
HuangC, LiuL, YouZ, et al.Managing keloid scars: From radiation therapy to actual and potential drug deliveries. Int Wound J, 2019; 16(3):852–859.
119.
MartinCJ, DattaA, LittlefieldC, et al.Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci Transl Med, 2020; 12(536):eaay8456.
120.
AndugulapatiSB, GourishettiK, TirunavalliSK, et al.Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems. Phytomedicine, 2020; 78:153298.
121.
IsakaY. Targeting TGF-β signaling in kidney fibrosis. Int J Mol Sci, 2018; 19(9):2532.
122.
McGaraughtyS, Davis-TaberRA, ZhuCZ, et al.Targeting anti-TGF-β therapy to fibrotic kidneys with a dual specificity antibody approach. J Am Soc Nephrol, 2017; 28(12):3616–3626.
123.
WangSH, ZuoYG. Thymic stromal lymphopoietin in cutaneous immune-mediated diseases. Front Immunol, 2021; 12:698522.
124.
OhMH, OhSY, YuJ, et al.IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol, 2011; 186(12):7232–7242.
125.
Menzies-GowA, CorrenJ, BourdinA, et al.Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med, 2021; 384(19):1800–1809.
126.
LimCP, PhanTT, LimIJ, et al.Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Oncogene, 2006; 25(39):5416–5425.
127.
WangY, HeG, TangH, et al.Aspirin inhibits inflammation and scar formation in the injury tendon healing through regulating JNK/STAT-3 signalling pathway. Cell Prolif, 2019; 52(4):e12650.
128.
ParkG, YoonBS, MoonJH, et al.Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. J Invest Dermatol, 2008; 128(10):2429–2441.
129.
HongYK, WuCH, LinYC, et al.ASC-J9 blocks cell proliferation and extracellular matrix production of keloid fibroblasts through inhibiting STAT3 signaling. Int J Mol Sci, 2022; 23(10):5549.
130.
ZhouBY, WangWB, WuXL, et al.Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization. Acta Pharmacol Sin, 2020; 41(9):1234–1245.
131.
LiangCJ, YenYH, HungLY, et al.Thalidomide inhibits fibronectin production in TGF-β1-treated normal and keloid fibroblasts via inhibition of the p38/Smad3 pathway. Biochem Pharmacol, 2013; 85(11):1594–1602.
132.
WuD, LiuX, JinZ. Placental mesenchymal stem cells-secreted proenkephalin suppresses the p38 MAPK signaling to block hyperproliferation of keloid fibroblasts. Tissue Cell, 2023; 85:102218.
133.
ChenY, ChenC, FangJ, et al.Targeting the Akt/PI3K/mTOR signaling pathway for complete eradication of keloid disease by sunitinib. Apoptosis, 2022; 27(11–12):812–824.
134.
WangZ, FongKD, PhanTT, et al.Increased transcriptional response to mechanical strain in keloid fibroblasts due to increased focal adhesion complex formation. J Cell Physiol, 2006; 206(2):510–517.
135.
FengF, LiuM, PanL, et al.Biomechanical regulatory factors and therapeutic targets in keloid fibrosis. Front Pharmacol, 2022; 13:906212.
136.
JemalI, SorianoS, ConteAL, et al.G protein-coupled receptor signalling potentiates the osmo-mechanical activation of TRPC5 channels. Pflugers Arch, 2014; 466(8):1635–1646.
137.
QinZ, XiaW, FisherGJ, et al.YAP/TAZ regulates TGF-β/Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal fibroblasts. Cell Commun Signal, 2018; 16(1):18.
138.
HeS, LiuX, YangY, et al.Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. Br J Dermatol, 2010; 162(3):538–546.
139.
O’ReillyS, CiechomskaM, CantR, et al.Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem, 2014; 289(14):9952–9960.
140.
ZhangD, LiB, ZhaoM. Therapeutic strategies by regulating interleukin family to suppress inflammation in hypertrophic scar and keloid. Front Pharmacol, 2021; 12:667763.
141.
UnahabhokhaT, SucontphuntA, NimmannitU, et al.Molecular signalings in keloid disease and current therapeutic approaches from natural based compounds. Pharm Biol, 2015; 53(3):457–463.
142.
WangW, QuM, XuL, et al.Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways. J Mol Med (Berl), 2016; 94(10):1181–1194.
143.
ZouYP, ShanXF, QiuJX, et al.Botulinum toxin type A inhibits M1 macrophage polarization by deactivation of JAK2/STAT1 and IκB/NFκB pathway and contributes to scar alleviation in aseptic skin wound healing. Biomed Pharmacother, 2024; 174:116468.
144.
BiM, SunP, LiD, et al.Intralesional injection of botulinum toxin type A compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid: A systematic review and meta-analysis. Med Sci Monit, 2019; 25:2950–2958.
TanKT, McGroutherDA, DayAJ, et al.Characterization of hyaluronan and TSG-6 in skin scarring: Differential distribution in keloid scars, normal scars and unscarred skin. J Eur Acad Dermatol Venereol, 2011; 25(3):317–327.
147.
QiY, JiangD, SindrilaruA, et al.TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol, 2014; 134(2):526–537.
148.
WangH, ChenZ, LiXJ, et al.Anti-inflammatory cytokine TSG-6 inhibits hypertrophic scar formation in a rabbit ear model. Eur J Pharmacol, 2015; 751:42–49.
149.
ZhaoJ, YuJ, XuY, et al.Epidermal HMGB1 activates dermal fibroblasts and causes hypertrophic scar formation in reduced hydration. J Invest Dermatol, 2018; 138(11):2322–2332.
150.
LimandjajaGC, NiessenFB, ScheperRJ, et al.The keloid disorder: Heterogeneity, histopathology, mechanisms and models. Front Cell Dev Biol, 2020; 8:360.
151.
OzawaT, OkamuraT, HaradaT, et al.Accumulation of glucose in keloids with FDG-PET. Ann Nucl Med, 2006; 20(1):41–44.
152.
LinL, WangY, LiuW, et al.BAMBI inhibits skin fibrosis in keloid through suppressing TGF-β1-induced hypernomic fibroblast cell proliferation and excessive accumulation of collagen I. Int J Clin Exp Med, 2015; 8(8):13227–13234.
153.
HillmerMP, MacLeodSM. Experimental keloid scar models: A review of methodological issues. J Cutan Med Surg, 2002; 6(4):354–359.
154.
YangGP, LimIJ, PhanTT, et al.From scarless fetal wounds to keloids: Molecular studies in wound healing. Wound Repair Regen, 2003; 11(6):411–418.
155.
ChoiY, JangHS, ShimJ, et al.3D keloid spheroid model: Development and application for personalized drug response prediction. Commun Biol, 2024; 7(1):1470.
